Acumen Pharmaceuticals, Inc. ABOS
We are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach targeting what we believe to be a key underlying cause of Alzheimer's disease, or AD. Alzheimer's disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death. Alzheimer's disease is currently estimated to affect approximately seven million people in the United States and approximately 55 million people worldwide and was the sixth-leading cause of death among individuals aged 65 and older in 2022 in the United States. Due to the aging population, patient populations in the United States impacted by AD are expected to grow to approximately 13 million people by 2050 without effective preventative measures or safe and effective disease-modifying treatments. By 2050, healthcare costs for AD in the United States alone are estimated to near $1 trillion.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $104.9M | $93.8M | $42.3M | $32.4M | $12.3M | $8.0M | — |
| SG&A | $18.9M | $20.2M | $18.8M | $12.9M | $7.3M | $1.4M | — |
| Total operating expenses | $123.8M | $114.0M | $61.1M | $45.2M | $19.6M | $9.3M | — |
| Operating income | -$123.8M | -$114.0M | -$61.1M | -$45.2M | -$19.6M | -$7.9M | — |
| Interest expense | $4.2M | $4.1M | $581.0K | $0 | — | — | — |
| Pre-tax income | -$121.3M | -$102.3M | -$52.4M | -$42.9M | -$100.6M | -$7.3M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$121.3M | -$102.3M | -$52.4M | -$42.9M | -$100.6M | -$7.3M | — |
| EPS, basic | -2.00 | -1.71 | -1.08 | -1.06 | -5.02 | — | — |
| EPS, diluted | -2.00 | -1.71 | -1.08 | -1.06 | -5.02 | -17.48 | — |
| Shares, diluted (wtd. avg.) | 60.6M | 60.0M | 48.6M | 40.6M | 20.1M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $54.0M | $35.6M | $67.1M | $130.1M | $122.2M | $43.8M | $6.6M |
| Short-term investments | $62.9M | $135.9M | $176.6M | $47.5M | $72.1M | — | — |
| Total current assets | $122.3M | $178.3M | $246.6M | $180.3M | $198.7M | $44.4M | — |
| Property, plant and equipment | $103.0K | $73.0K | $122.0K | $165.0K | $36.0K | — | — |
| Total assets | $122.8M | $239.0M | $310.1M | $196.6M | $230.3M | $44.4M | — |
| Accounts payable | $554.0K | $5.6M | $1.4M | $1.6M | $1.1M | $531.0K | — |
| Short-term debt | $8.8M | $0 | — | — | — | — | — |
| Total current liabilities | $30.0M | $27.6M | $13.0M | $7.8M | $5.1M | — | — |
| Long-term debt | $22.4M | $29.4M | $29.9M | $0 | — | — | — |
| Total liabilities | $52.4M | $57.2M | $43.2M | $7.8M | $5.1M | $6.4M | — |
| Retained earnings | -$446.5M | -$325.1M | -$222.8M | -$170.4M | -$127.6M | -$27.0M | — |
| Total equity | $70.4M | $181.8M | $267.0M | $188.8M | $225.2M | -$18.6M | -$11.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$115.5M | -$86.2M | -$43.1M | -$35.2M | -$18.0M | -$7.5M | — |
| Depreciation and amortisation | $58.0K | $63.0K | $61.0K | $32.0K | $4.0K | — | — |
| Stock-based compensation | $9.9M | $9.6M | $6.1M | $3.1M | $922.0K | $154.0K | — |
| Capital expenditure | $88.0K | $16.0K | $21.0K | $161.0K | $40.0K | — | — |
| Investing cash flow | $133.9M | $48.0M | -$171.7M | $39.2M | -$104.1M | — | — |
| Financing cash flow | -$34.0K | $6.9M | $151.8M | $3.9M | $200.5M | $44.7M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-021413.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$7.3M | -$100.6M | -$42.9M | -$52.4M | -$102.3M | -$121.3M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |